The Potential of Fractional Exhaled Nitric Oxide as a Biomarker in Predicting and Optimizing Use of Treatment in Asthma

Main Article Content

Hirowati Ali
Salsabila Faiha Wiendra Rasya
Muhammad Abi Ghoffari Siregar

Abstract

Asthma affects the respiratory system and causes airway inflammation. The indication of asthma includes a triad of airway inflammation, hyperresponsiveness, and obstruction. Nitric Oxide (NO) is a gas that is exhaled and is a sign of airway inflammation. NO levels in the exhaled breath of patients with type 2 asthma are elevated, and fractional exhaled nitric oxide (FeNO) is an objective biomarker of airway inflammation. Measurements of FeNO are noninvasive, require minimal patient effort, and are easy to collect in clinical settings. The current review is a systematic review performed using PubMed, Science Direct, and Google Scholar according to The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) guidelines. This review discusses the entanglement of understanding FeNO measurement and supplementing existing diagnostic and assessment tools for inflammatory lung diseases. Monitoring FeNO can also help identify different asthma phenotypes within the asthma syndrome and suggest the optimal administration of inhaled corticosteroids (ICS) as elevated FeNO levels indicate ICS response. Non-adherence to ICS is a significant contributor to the failure of asthma treatment. A FeNO suppression test can be done to determine non-adherence. FeNO levels should be used with a careful history, conventional spirometric testing with bronchodilator reversibility, measures of bronchial hyperreactivity using methacholine, and other measures of eosinophilic inflammation, such as a peripheral blood eosinophil cell count. FeNO is more sensitive and specific when paired with other lung function tests.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Ali H, Rasya SFW, Siregar MAG. The Potential of Fractional Exhaled Nitric Oxide as a Biomarker in Predicting and Optimizing Use of Treatment in Asthma. SEE J Immunol [Internet]. 2023 Jun. 6 [cited 2023 Sep. 23];6(1):18-23. Available from: https://seejim.eu/index.php/seejim/article/view/6033
Section
Basic Immunology

References

Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. https://doi.org/10.3389/fped.2019.00246 PMid:31275909

World Health Organization. Asthma. Geneva: World Health Organization; 2022. Available from: https://www.who.int/respiratory/asthma/causes/en [Last accessed on 2023 Jan 14].

Yung JA, Fuseini H, Newcomb DC. Sex hormones, gender and asthma. HHS Public Access. 2019;176:139-48.

Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219-33. https://doi.org/10.1007/s12016-018-8712-1 PMid:30206782

Padem N, Saltoun C. Classification of asthma. Allergy Asthma Proc. 2019;40(6):385-8. https://doi.org/10.2500/aap.2019.40.4253 PMid:31690376

Breiteneder H, Peng YQ, Agache I, Diamant Z, Eiwegger T, Fokkens WJ, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75(12):3039-68. https://doi.org/10.1111/all.14582 PMid:32893900

Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783-800. https://doi.org/10.1016/ S0140-6736(17)33311-1 PMid:29273246

Busse WW, Kraft M, Rabe KF, Deniz Y, Rowe PJ, Ruddy M, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with Type 2 inflammation. Eur Respir J. 2021;58(2):2003393. https://doi.org/10.1183/13993003.03393-2020 PMid:33542055

Rupani H, Chauhan AJ. Measurement of FeNO in asthma: What the hospital doctor needs to know. Br J Hosp Med (Lond). 2019;80(2):99-104. https://doi.org/10.12968/hmed.2019.80.2.99 PMid:30746998

Russell RJ, Brightling CE. Pathogenesis of asthma: Implications for precision medicine. Clin Sci (Lond). 2017;131(14):1723-35. https://doi.org/10.1042/CS20160253 PMid:28667070

Hoyte FC, Gross LM, Katial RK. Exhaled nitric oxide: An update. Immunol Allergy Clin North Am. 2018;38(4):573-85. https://doi.org/10.1016/j.iac.2018.06.001 PMid:30342580

Tiotiu A. Biomarkers in asthma: State of the art. Asthma Res Pract. 2018;4:10. https://doi.org/10.1186/s40733-018-0047-4 PMid:30598830

Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019;68(2):158-66. https://doi.org.10.1016/j.alit.2019.01.004 PMid:30792118

Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med. 2015;7(301):301ra129. https://doi.org/10.1126/scitranslmed.aab3142 PMid:26290411

Mastalerz L, Celejewska-Wójcik N, Ćmiel A, Wójcik K, Szaleniec J, Hydzik-Sobocińska K, et al. Non-eosinophilic asthma in nonsteroidal anti-inflammatory drug exacerbated respiratory disease. Clin Transl Allergy. 2023;13(3):e12235. https://doi.org/10.1002/clt2.12235 PMid:36973957

National Heart, Lung, and Blood Institute. What is Fractional Exhaled Nitric Oxide (FeNO) Testing? United States: National Institute of Health; 2020. p. 20-HL-8146.

Högman M, Lehtimäki L, Dinh-Xuan AT. Utilising exhaled nitric oxide information to enhance diagnosis and therapy of respiratory disease-current evidence for clinical practice and proposals to improve the methodology. Expert Rev Respir Med. 2017;11(12):101-9. https://doi.org/10.1080/17476348.2017.1281746 PMid:28076986

Ricciardolo FL, Sprio AE, Baroso A, Gallo F, Riccardi E, Bertolini F, et al. Characterization of T2-low and T2-high asthma phenotypes in real-life. Biomedicines. 2021;9(11):1684. https://doi.org/10.3390/biomedicines9111684 PMid:34829913

Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, et al. Cluster analysis of inflammatory biomarker expression in the international severe asthma registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-8.e7. https://doi.org/10.1016/j.jaip.2021.02.059 PMid:33744476

Khatri SB, Iaccarino JM, BarochiaA, Soghier I,Akuthota P, BradyA, et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2021;204(10):E97-109. https://doi.org/10.1164/rccm.202109-2093ST PMid:34779751

Gao J, Wu F. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy Asthma Clin Immunol. 2018;14:21. https://doi.org/10.1186/s13223-018-0248-7 PMid:29796021

American Thoracic Society. New Clinical Practice Guideline on Fractional Exhaled Nitric Oxide (FeNO) to Help Guide Asthma Treatment. New York: American Thoracic Society; 2021.

Zhu H, Zhang R, Hao C, Yu X, Tian Z, Yuan Y. Fractional exhaled nitric oxide (FeNO) combined with pulmonary function parameters shows increased sensitivity and specificity for the diagnosis of cough variant asthma in children. Med Sci Monit.

;25:3832-8. https://doi.org/10.12659/msm.913761 PMid:31120043

Wang Y, Zhao L, Chen F, Guo Y, Ma H, Han B, et al. Diagnostic value of fractional exhaled nitric oxide and small Airway function in differentiating cough-variant asthma from typical asthma. Can Respir J. 2021;2021:9954411. https://doi.org/10.1155/2021/9954411 PMid:34457097